Lonza secures exclusive license to use Qurient CDK7 inhibitors for dual-payload ADCs

By Public Technologies
  • Lonza signed an exclusive license deal with Qurient for use of Qurient’s CDK7 inhibitors in dual-payload antibody-drug conjugates.
  • Collaboration launches SYN-duo® CC, combining exatecan with a CDK7 inhibitor as an off-the-shelf linker-payload for ADC developers.
  • Lonza can create additional dual-payload combinations pairing the CDK7 inhibitor with other payloads on its proprietary ADC platform.
  • Move expands Lonza’s proprietary technology offering, aiming to strengthen its position in the growing ADC market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2413778_en) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.